Top

Administration and Policy in Mental Health and Mental Health Services Research

Published in:

01-05-2008 | Original Paper

Effects of a Psychotherapeutic Drug Prior Authorization (PA) Requirement on Patients and Providers: A Providers’ Perspective

Authors: Carolyn M. Brown, Kristin Richards, Karen L. Rascati, Paul Gavaza, Zach Corbell, Woodie Zachry, Glenn A. Phillips

Published in: Administration and Policy in Mental Health and Mental Health Services Research | Issue 3/2008

Abstract

This study describes the effects of a Texas Medicaid PA requirement for psychotherapeutic medications from the perspective of mental health care providers. Three focus groups were conducted and a content analysis was performed on the generated transcripts. Providers identified five categories of issues that are relevant to the PA process: (1) system/administrative factors; (2) costs/ outcomes; (3) prescribing issues; (4) evaluation criteria; and (5) patient–provider relationship and patient visit. Administrative burden and unintended patient outcomes were the most frequently reported issues related to PA. However, all five issues represent important factors that providers deal with when caring for patients with mental illness.

Available only for authorised users

Bernasek, C., Farkas, J., Felman, H., et al. (2003). Case study: Michigan’s Medicaid prescription drug benefit. Washington: Henry Kaiser Family Foundation.

Bull, S. A., Hunkeler, E. M., Lee, J. Y., et al. (2002). Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy, 36, 578–584.PubMedCrossRef

Delate, T., Mager, D. E., Sheth, J., & Motheral, B. R. (2005). Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. American Journal of Managed Care, 11, SP29–SP36.

Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007). Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. Journal of the American Medical Association, 298, 61–69.PubMedCrossRef

Hodgkin, D., Horgan, C. M., Garnick, D. W., et al. (2007). Management of access to branded psychotropic medications in private health plans. Clinical Therapeutics, 29, 371–380.PubMedCrossRef

Huskamp, H. A. (2003). Managing psychotropic drug costs: Will formularies work? Health Affairs, 22, 84–96.PubMedCrossRef

Ketcham, J. D., & Epstein, A. J. (2006). Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives? Pharmacoeconomics, 24(Suppl. 3), 27–40.PubMed

Koyanagi, C., Forquer, S., & Alfano, E. (2005). Medicaid policies to contain psychiatric drug costs. Health Affairs, 24, 536–544.PubMedCrossRef

Lichtenberg, F. R. (2005). The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. American Journal of Managed Care, 11, SP7–SP13.PubMed

MacKinnon, N. J., & Kumar, R. (2001). Prior authorization programs: A critical review of the literature. Journal of Managed Care Pharmacy, 7, 297–302.

MaineCare Advisory Committee’s Prior Authorization Subcommittee, (2005). Report and recommendations on prior authorization for prescription drugs in the MaineCare and Drugs for the Elderly Programs. Augusta, ME.

Marshall, C., & Rossman, G. B. (1995). Designing qualitative research. Thousand Oaks: Sage Publications.

Murawski, M. M., & Abdelgawad, T. (2005). Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. American Journal of Managed Care, 11, SP35–SP42.PubMed

National Pharmaceutical Council. (2007). Pharmaceutical benefits under state medical assistance programs, 2005/2006. Reston, VA.

Patton, M. Q. (1990). Qualitative evaluation and research methods. Newbury Park: Sage Publications.

Perkins, D. O. (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63, 1121–1128.PubMed

Ridley, D. B., & Axelsen, K. J. (2006). Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics, 24(Suppl. 3), 65–78.PubMed

Soumerai, S. B. (2004). Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs, 23, 135–146.PubMedCrossRef

Texas Health and Human Services Commission (2006). Preferred drug list annual report. Retrieved August 29, 2007, from http://www.hhsc.state.tx.us/HCF/vdp/pt/PDL_Program.html.

Texas Medicaid preferred drug list and prior authorization criteria (2007). Retrieved March 3, 2007, from http://www.hhsc.state.tx.us/HCF/vdp/pt/PDL_Program.html.

Tilly, J., & Elam, L. (2003). Prior authorization for Medicaid prescription drugs in five states: Lessons for policy makers. Washington: Henry Kaiser Family Foundation.

Virabhak, S., & Shinogle, J. A. (2005). Physicians’ prescribing responses to a restricted formulary: The impact of Medicaid preferred drug lists in Illinois and Louisiana. American Journal of Managed Care, 11, SP14–SP20.PubMed

Wang, Y. R. (2006). Spillover effects of restrictive drug formularies in the statin class: A descriptive study of the Medicaid preferred drug list in Texas. Managed Care Interface, 19, 32–34.PubMed

West, J. C., Wilk, J. E., Muszynski, I. L., et al. (2007). Medication access and continuity: The experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescriptions drug benefit. American Journal of Psychiatry, 164, 789–796.PubMedCrossRef

Wilson, J., Axelsen, K., & Tang, S. (2005). Medicaid prescription drug access restrictions: Exploring the effect on patient persistence with hypertension medications. American Journal of Managed Care, 11, SP27–SP34.PubMed

Title: Effects of a Psychotherapeutic Drug Prior Authorization (PA) Requirement on Patients and Providers: A Providers’ Perspective
Authors: Carolyn M. Brown
Kristin Richards
Karen L. Rascati
Paul Gavaza
Zach Corbell
Woodie Zachry
Glenn A. Phillips
Publication date: 01-05-2008
Publisher: Springer US
Published in: Administration and Policy in Mental Health and Mental Health Services Research / Issue 3/2008
Print ISSN: 0894-587X
Electronic ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-007-0158-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of a Psychotherapeutic Drug Prior Authorization (PA) Requirement on Patients and Providers: A Providers’ Perspective

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Organizational Capacity Needs of Consumer-Run Organizations

Improving the Effectiveness of Mental Health Services

How Parents Seek Help for Children with Mental Health Problems

Outcomes for Youth Residential Treatment Programs Using Administrative Data from the Child Welfare System: A Risk-Adjustment Application

Variations in Medicaid Mental Health Service Use and Cost for Children

Factors Influencing Consumer Outcome Monitoring in Implementation of Evidence-Based Practices: Results from the National EBP Implementation Project